School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Auckland Cancer Society Research Centre, Faculty of Medical & Health Sciences, and Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand.
Eur J Hosp Pharm. 2023 Mar;30(e1):e48-e54. doi: 10.1136/ejhpharm-2021-003003. Epub 2021 Oct 18.
Bupivacaine hydrochloride (BH) and ketorolac tromethamine (KT) are commonly used in parenteral admixtures to manage postoperative pain. However, stability and compatibility data for these admixtures applicable to current practice are limited, posing the patient to potential risk.
The stability of BH/KT admixtures in commonly used parenteral fluids was studied in Eppendorf tubes and glass vials at ambient room temperature using a newly developed and validated stability-indicating high-performance liquid chromatography (HPLC) method capable of the simultaneous quantification of both drugs. The chemical compatibility of BH/KT was assessed using Fourier transform infrared spectroscopy (FTIR) and thermal analysis. Additionally, the validity of the developed HPLC method for the quantification of BH/KT in human plasma was evaluated.
BH and KT demonstrated <10% loss of their initial concentrations when prepared in Ringer, normal saline or dextrose solution at ambient temperature for up to 4 weeks. FTIR and thermal analysis demonstrated mild intermolecular interactions between BH and KT in solution, with no evidence of incompatibility. The developed HPLC method demonstrated satisfactory accuracy and precision for the simultaneous quantification of BH and KT in human plasma over the range of 0.2-3.2 µg·mL.
BH/KT parenteral admixtures are chemically stable for a period of 4 weeks when stored at room temperature. The stability-indicating HPLC method is valid for BH/KT simultaneous determination in human plasma, facilitating pharmacokinetics studies.
盐酸布比卡因(BH)和酮咯酸氨丁三醇(KT)常用于配制静脉混合液以管理术后疼痛。然而,目前适用于实际应用的这些混合液的稳定性和相容性数据有限,使患者面临潜在风险。
采用新开发并经验证的具有同时定量两种药物能力的稳定性指示高效液相色谱法(HPLC),在环境室温下的 Eppendorf 管和玻璃小瓶中研究 BH/KT 混合物在常用的静脉输液中的稳定性。采用傅立叶变换红外光谱(FTIR)和热分析评估 BH/KT 的化学相容性。此外,还评估了开发的 HPLC 方法用于定量人血浆中 BH/KT 的有效性。
当在环境温度下将 BH 和 KT 分别制备于林格氏液、生理盐水或葡萄糖溶液中时,在长达 4 周的时间内,其初始浓度损失均<10%。FTIR 和热分析表明,BH 和 KT 在溶液中存在轻微的分子间相互作用,但无不相容的证据。所开发的 HPLC 方法在 0.2-3.2μg·mL 的范围内对人血浆中 BH 和 KT 的同时定量具有令人满意的准确度和精密度。
当储存在室温下时,BH/KT 静脉混合液在 4 周内化学稳定。该稳定性指示 HPLC 方法可用于 BH/KT 在人血浆中的同时测定,有利于药代动力学研究。